U.S. markets open in 10 minutes
  • S&P Futures

    3,956.25
    +19.50 (+0.50%)
     
  • Dow Futures

    33,741.00
    +116.00 (+0.34%)
     
  • Nasdaq Futures

    11,566.50
    +57.00 (+0.50%)
     
  • Russell 2000 Futures

    1,817.60
    +9.60 (+0.53%)
     
  • Crude Oil

    74.33
    +2.32 (+3.22%)
     
  • Gold

    1,800.70
    +2.70 (+0.15%)
     
  • Silver

    23.23
    +0.31 (+1.34%)
     
  • EUR/USD

    1.0523
    +0.0009 (+0.08%)
     
  • 10-Yr Bond

    3.4750
    +0.0670 (+1.97%)
     
  • Vix

    22.71
    +0.54 (+2.44%)
     
  • GBP/USD

    1.2205
    0.0000 (-0.00%)
     
  • USD/JPY

    136.7100
    +0.1860 (+0.14%)
     
  • BTC-USD

    16,852.40
    -5.34 (-0.03%)
     
  • CMC Crypto 200

    396.51
    -5.53 (-1.37%)
     
  • FTSE 100

    7,491.13
    +1.94 (+0.03%)
     
  • Nikkei 225

    27,574.43
    -111.97 (-0.40%)
     

ASLAN Pharmaceuticals Presents New Data From Atopic Dermatitis Candidate

  • ASLAN Pharmaceuticals (NASDAQ: ASLNannounced the presentation of new translational eblasakimab data at the Annual European Society for Dermatological Research (ESDR) Meeting.

  • The company noted the new translational data presented at ESDR provide novel and differentiated mechanistic insights into IL-13Rα1 mediated cytokine signaling in atopic dermatitis (AD).

  • First poster data showed increased IL-13Rα1 expression on mast cells and eosinophils in skin samples from atopic dermatitis (AD) patients, reinforcing the central role of IL-13Rα1.

  • Eblasakimab significantly reduced neuronal itch sensitization caused by distinct IL-4 and IL-13 itch pathways.

  • An emerging role of IL-13Rα1 signaling in mediating neuronal excitability and sensitivity beyond AD was identified.

  • Earlier this month, ASLAN announced a new clinical trial of eblasakimab for moderate-to-severe atopic dermatitis (AD) in adult patients who have previously been treated with dupilumab.

  • Dubbed TREK-DX trial, the study is expected to enroll the first patient in the fourth quarter of 2022.

  • In January 2022, ASLAN initiated the TREK-AD Phase 2b trial to evaluate the safety and efficacy of eblasakimab in moderate-to-severe AD patients. Topline data is expected in the first half of 2023.

  • Price Action: ASLN shares are up 1.64% at $0.62 on the last check Wednesday.

See more from Benzinga

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.